|Ms. Linda F. Powers J.D.||Chairperson, Chief Exec. Officer, Pres and Chief Financial Officer||502k||N/A||61|
|Dr. Alton L. Boynton Ph.D.||Founder, Chief Scientific Officer, Sec. and Director||325k||N/A||72|
|Dr. Marnix L. Bosch Ph.D., MBA||Chief Technical Officer||375k||N/A||58|
|Mr. Leslie J. Goldman||Sr. VP of Bus. Devel.||375k||N/A||72|
|Dr. Anthony E. Maida III, MA, MBA, Ph.D.||Sr. VP of Clinical Research||N/A||N/A||65|
Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops immunotherapy products to treat cancer in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patients own immune system to attack cancer. The companys products include DCVax-L, which is under Phase III brain cancer trial for treating brain cancer; DCVax-Direct that is under Phase I/II clinical trial for various types of inoperable solid tumor cancers; and DCVax-Prostate, which is under Phase III for prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
Northwest Biotherapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 10. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 8; Compensation: 8.